References
Robinson R. (2004) RNAi Therapeutics: How Likely, How Soon?. PLoS Biol 2(1): e28. Published January 20, 2004.
Fire et al. Potent and Specific Genetic Interference by Double-Stranded RNA in Caenorhabditis elegans. Nature. 1998 Feb 19;391 (6669): 806:11.
Clark J, Tyson K, Stanton B, et al. Patent Pools: A Solution to the Problem of Access in Biotechnology Patents? USPTO white paper (December 2000).
Intel Foundation Young Scientist Award: Targeting Cancer Cells. Madiraju, Anila (2003)
siRNA in Drug Discovery and Development Conference (Strategic Research Institute). The Intellectual Property Morass of siRNA (speech and interview). Warburg, Richard J. 2004
BioScan: The Worldwide Biotech Industry Reporting Service. Thomson-BioWorld Publishing Group, Millay, Amanda. 2004
Further acknowledgements:
Nassim Usman, Ph.D., COO, Sirna Therapeutics Inc. Interview 2004
Steve Kriegsman, President and CEO, CytRx Inc. Interview 2004
John McKinley, Chairman and CEO, Benitec Ltd. Interview 2004
Sara Cunningham, COO, Benitec Inc. Interview 2004
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
Fax: 1-770-810-3145
BioWorld.salessupport@thomsonreuters.com
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
BioWorld.support@thomsonreuters.com
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Free Ezine
Sign up for Highlights FREE e-mail newsletter